Chennai, Nov 20 (UNI) Shreya Life Sciences today announced the launch of world's first oral insulin, a recombinant DNA human insulin buccal spray under the brand name ''Oral Recosulin''.
Announcing the launch of the new product, which would be a boon to type I and type II diabetics, Mr Ram Shelat, Director Shreya Life Sciences said the company had develped the product in association with US based Generex Biotechnology.
''Oral Recosulin provides freedom from limitations of conventional insulin therapy/devices. The new technology delivers insulin through buccal mucosa directly to the vascular system'', he said.
It was an alternative available for diabetics who have an acute injection phobia. ''Oral Recosulin is a simple solution for a worldwide problem, as diabetics would prefer buccal delivery of the drug to injections''.
Citing a World Health Organisation (WHO) study, he said the estimated number of diabetic patients in the country would rise to 57 million by the year 2025, making India, home to the largest diabetic population in the world.
He said the Indian diabetic market was estimated to be about Rs 1722 crore, with a growth rate of 20 per cent.
The insulin market was worth Rs 520 crore, growing at a rate of 24 per cent, while the oral anti diabetic market is Rs 1200 crore, growing at the rate of Rs 20 crore.
UNI WS VV SLD UCS1934